Research and Markets: Generic Drug Opportunity Assessment - Eltrombopag ... The Herald | HeraldOnline.com (press release) In the U.S., Promacta is already indicated for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. The Market. Immune thrombocytopenic purpura (ITP) is ... |
